Analysis of the efficacy of gonadotropin-releasing hormone agonist combined with drospirenone and ethinylestradiol in postoperative patients with ovarian endometriotic cyst
Objective To investigate the efficacy of gonadotropin-releasing hormone agonist(GnRH-a)combined with drospirenone and ethinylestradiol in postoperative patients with ovarian endometriotic cyst.Methods A total of 88 patients with ovarian endometriotic cyst treated in Dazhou Integrated Traditional Chinese and Western Medicine Hospital from December 2020 to August 2022 were selected as study objects and randomly divided into observation group(n=44)and control group(n=44).All patients received laparoscopic cyst enucleation of ovarian endometriosis.Control group patients were subcutaneously injected with leuprorelin acetate microspheres,while observation group patients were combined with drospirenone and ethinylestradiol tablets.The serum levels of human epididymal protein 4(HE4),carbohydrate antigen 125(CA1 25),carbohydrate antigen 199(CA1 99),estradiol(E2),luteinizing hormone(LH),follicle stimulating hormone(FSH),anti-Müllerian hormone(AMH)and the number of ovarian antral follicles(AFC)were compared between the two groups.Visual analogue score(VAS)and numeric rating scale(NRS)were used to evaluate the degree of patients'subjective pain,and the incidence of adverse events and disease recurrence rate were compared between the two groups.Results The serum HE4,CA125,CA199,E2,LH,VAS and NRS in both group patients were significantly lower than those before treatment,of which the observation group patients were much lower than control group(P＜0.05);after treatment,the AMH level in the control group was significantly lower than that in the observation group(P＜0.05).The recurrence rate of ovarian endometriosis in the observation group was significantly lower(P＜0.05).Conclusions GnRH-a combined with drospirenone and ethinylestradiol can significantly reduce the degree of pain and the level of tumor markers in postoperative patients with ovarian endometriotic cyst,which is beneficial to the recovery of sex hormone levels and injured ovarian reserve function.At the same time,compared with GnRH-a monotherapy,the combined therapy can effectively reduce the recurrence rate of disease and the incidence of adverse reactions.
Gonadotropin-releasing hormone agonistDrospirenone and ethinylestradiolOvarian endometriosis cystEfficacy
NETL
NSTL
万方数据
